PACS Group (PACS) Q1 2026 earnings review
Profitability Accelerates as Integration Engine Matures
PACS Group's Q1 2026 results show a business successfully digesting its massive 2024 acquisition spree. While revenue growth decelerated to 11.2% YoY, the bottom line exploded: Net Income surged 184% and Adjusted EBITDA jumped 74.6%. The beat was fueled by the 'Ramping' facility cohort pushing toward mature occupancy levels and a $16.3M windfall from California's quality incentive program. Backed by $236M in quarterly operating cash flow, management authorized a $250M buyback and raised FY26 EBITDA guidance by $50M at the midpoint, stripping out future M&A assumptions to showcase pure organic strength.
🐂 Bull Case
Ramping facilities saw occupancy jump 250 bps to 88.9%, driving a 33.7% surge in segment revenue. The localized turnaround model is efficiently converting 2024's acquisitions into high-margin assets.
The initiation of a $250M share repurchase program, combined with removing M&A from future guidance, signals a confident shift toward returning capital and driving per-share value.
🐻 Bear Case
A meaningful portion of the EBITDA beat came from a $16.3M California WQIP payment. Management admitted these payments are unpredictable in timing and amount, creating ongoing lumpiness.
Average daily Medicare rates in the 'New' facility cohort fell sharply from $771 to $732 YoY, indicating that early-stage turnarounds continue to face significant pricing and acuity pressure.
⚖️ Verdict: 🟢
Bullish. The company is proving its core thesis: it can buy broken facilities and fix them. Accelerating profitability, organic guidance raises, and aggressive cash generation vastly outweigh the lumpiness of state funding.
Key Themes
Ramping Cohort Execution Driving Margin Expansion
The operational engine is working exactly as advertised. Facilities in the 'Ramping' cohort (owned 18-36 months) saw skilled mix by nursing days increase 360 bps YoY to 27.8%, while occupancy rose from 86.4% to 88.9%. This operational leverage resulted in a 33.7% YoY revenue surge for the cohort, serving as the primary bridge to the total company's 74.6% EBITDA growth.
California WQIP Highlights Quality Leverage
PACS recorded a $16.3M EBITDA benefit from California’s Workforce & Quality Incentive Program (WQIP). By maintaining a portfolio where 78.4% of facilities boast 4- or 5-star CMS Quality Measure ratings (average of 4.4 for mature assets), PACS is successfully monetizing its clinical outcomes in states that aggressively tie reimbursement to care quality.
Strategic Real Estate Internalization
PACS is heavily mitigating its lease vulnerability. During Q1, the company deployed $86.5M into strategic real estate investments, capitalizing on its 59 available purchase options. By converting operating leases into owned hard assets, the company locks in fixed costs and improves long-term free cash flow conversion.
Guidance Strips Out M&A Strategy
Management removed $120M in previously expected acquisition-related revenue from its FY26 guidance. While the headline revenue number was maintained (implying a massive organic beat), explicitly sidelining M&A from the financial model marks a departure for a company that added 106 facilities in 2024. It suggests external growth will remain muted as management digests past deals.
Pricing Weakness in New Facilities
While total company average daily rates improved, the 'New' facility cohort struggled. The average daily Medicare rate for this group fell 5.1% YoY to $732.31, and Medicaid rates in this cohort also trailed the company average. This data point reveals that the initial 18 months of a turnaround remain highly dilutive to blended rates.
Other KPIs
Accelerating/Stable. Same-store revenue for the 284 facilities operated since the beginning of 2025 grew 8.0% YoY. This clean metric strips out the noise of acquisitions and divestitures, proving that base pricing and volume dynamics remain structurally healthy.
Massive cash generation in a single quarter, up from $150.2M in 25Q1. This fully funded the quarter's $126.9M in investing activities (including real estate purchases) without requiring debt expansion, resulting in net leverage dropping to a negligible 0.1x.
Guidance
Accelerating. Raised significantly from the prior range of $555M-$575M. At the midpoint, this represents ~22% growth over 2025 actuals, driven entirely by organic cohort maturation rather than new acquisitions.
Stable. The headline range was reaffirmed, but the underlying quality improved dramatically. The company removed $120M of assumed M&A contribution, meaning organic revenue expectations were effectively raised to backfill the missing acquisition volume.
Key Questions
Visibility on State Incentives
The $16.3M WQIP payment was excluded from prior guidance due to uncertainty. How much visibility do you have into similar state-level quality incentive payments for the remainder of FY26, and are any included in the revised EBITDA guide?
Rate Pressures in New Cohort
Average daily Medicare rates in the 'New' facility cohort fell from $771 to $732 YoY. Is this purely a function of the geographic mix of recently acquired facilities, or are you seeing a deliberate shift in acuity mix during the initial turnaround phase?
Capital Allocation Hierarchy
With the new $250M share repurchase authorization and M&A stripped from guidance, how does the Investment Committee weigh buybacks versus external acquisitions right now? Does the buyback signal that current market multiples are too high for M&A?